Non-interventional Clinical Trial, to Assess the Efficacy, Safety and Tolerability of Ciclesonide 200 Mcg Once Daily, Applied as a Nasal Spray for Four Weeks, in the Treatment of Intermittent and Persistent Rhinitis

Trial Profile

Non-interventional Clinical Trial, to Assess the Efficacy, Safety and Tolerability of Ciclesonide 200 Mcg Once Daily, Applied as a Nasal Spray for Four Weeks, in the Treatment of Intermittent and Persistent Rhinitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Allergic rhinitis; Rhinitis
  • Focus Therapeutic Use
  • Acronyms SISRIP
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Sep 2012 Trial company changed from Nycomed to Takeda Mexico as reported by ClinicalTrials.gov.
    • 31 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top